Dynavax TechnologiesDVAX
DVAX
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
68% more call options, than puts
Call options by funds: $8.17M | Put options by funds: $4.87M
34% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 29
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
21% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 80
15% more capital invested
Capital invested by funds: $1.45B [Q3] → $1.67B (+$224M) [Q4]
2% more funds holding
Funds holding: 250 [Q3] → 255 (+5) [Q4]
0.19% more ownership
Funds ownership: 99.12% [Q3] → 99.31% (+0.19%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
12%
downside
Avg. target
$25
85%
upside
High target
$33
141%
upside
3 analyst ratings
2 positive
67%
0 neutral
0%
1 negative
33%
Citizens Capital Markets Jason Butler 35% 1-year accuracy 15 / 43 met price target | 141%upside $33 | Market Outperform Maintained | 21 Feb 2025 |
HC Wainwright & Co. Edward White 26% 1-year accuracy 39 / 148 met price target | 126%upside $31 | Buy Reiterated | 21 Feb 2025 |
Goldman Sachs Paul Choi 40% 1-year accuracy 4 / 10 met price target | 12%downside $12 | Sell Downgraded | 11 Feb 2025 |
Financial journalist opinion
Based on 13 articles about DVAX published over the past 30 days
Positive
Zacks Investment Research
1 day ago
Wall Street Analysts See an 83.1% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?
The consensus price target hints at an 83.1% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Business Wire
3 days ago
Deep Track Capital Sends Letter to Dynavax Technologies' Board of Directors
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.34% of the Company's outstanding shares, today sent a letter to the Company's Board of Directors (the “Board”) related to Deep Track's nomination of four highly qualified candidates for election to the Company's Board of Directors.
Neutral
PRNewsWire
1 week ago
Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase
Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new money Dynavax repurchased ~$8 million of the Company's common stock in connection with this transaction EMERYVILLE, Calif. , March 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and subscription agreements (the "Exchange Agreements") with a limited number of holders of its outstanding 2.50% Convertible Senior Notes due 2026 (the "2026 Notes") and one new investor, pursuant to which the Company will issue $225 million aggregate principal amount of 2.0% Convertible Senior Notes due 2030 (the "New Notes") comprised of (i) an exchange for the retirement of approximately $185 million in aggregate principal amount of existing 2026 Notes, and (ii) approximately $40 million of New Notes issued to existing holders and one new investor (the "Transactions").
Positive
Seeking Alpha
1 week ago
Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share
Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its superior efficacy and compliance compared to previous hepatitis B vaccines. Heplisav-B should eventually garner 60% of a market that is predicted to grow to $900 million in the U.S. by 2030.
Neutral
PRNewsWire
2 weeks ago
Dynavax to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m.
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 81.92%: Read This Before Placing a Bet
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Seeking Alpha
2 weeks ago
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Roy Buchanan - Citizens Jonathan Miller - Evercore ISI Phil Nadeau - TD Cowen Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technologies' Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Positive
Zacks Investment Research
2 weeks ago
Dynavax Technologies (DVAX) Surpasses Q4 Earnings and Revenue Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to break-even earnings per share a year ago.
Neutral
PRNewsWire
2 weeks ago
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected in Q3 2025 Plan to initiate Phase 2 trial for plague vaccine in Q3 2025 Expect completion of $200 million share repurchase program in 2025 Conference call today at 4:30 p.m. ET/1:30 p.m.
Neutral
PRNewsWire
3 weeks ago
Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy
Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif. , Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value.
Charts implemented using Lightweight Charts™